Global syphilis testing market is anticipated to witness an exponential growth in the forecast period. Syphilis is a sexually transmitted infection caused by the Treponema palladium bacterium. The factors that propel the growth of the market include increase in occurrence of syphilis, increasing incidences of syphilis, implementation of national screening plans, rising acceptance of novel technologies such as Darkfield microscopy, Enzyme Immunoassay (EIA) tests, and Micro hemagglutination (MHA-TP) assay that enables improved and faster screening results.
On the other hand, there are factors that may hamper the growth of the market including the lack of trained professionals, and a shortage of these experts in hospitals and diagnostic centers. Syphilis testing market is anticipated to expand at a significant CAGR in the upcoming period as the scope, product types, and its applications are increasing across the globe.
The new trend gaining drive in the market is surge in premarital screening. Premarital screening is a fitness valuation test for soon-to-be-married couples who are tested for the possibility of genetic diseases, transmissible diseases and infectious diseases. The market could be explored by type, product, technology, screening test type, and geography.
Get Sample Copy of this Report @
The market could be explored by Product as Assay/Consumables, Instruments. The market could be explored by type as Primary Syphilis and Secondary Syphilis. Based on technology, the market could span POC testing and Conventional testing. The “Conventional testing” segment led the syphilis testing market in 2017 and will continue to lead in the forecast period. The key factors that may be attributed to the growth of the market include the capacity of this conventional testing technology to notice several stages of syphilis.
The market could be explored based on screening test type as Rapid plasma reagin (RPR) test, Venereal disease research laboratory (VDRL) test, Fluorescent treponemal antibody absorption (FTA-ABS) test, Enzyme immunoassay (EIA) test, Treponema pallidum particle agglutination assay (TPPA), Micro hemagglutination assay (MHA-TP), and Darkfield microscopy.
LAMEA and the Asia Pacific accounted for the major share of the syphilis testing market in 2017 and will continue to lead in the forecast period. The factors that could be attributed to the growth include higher acceptance rates for technologically highly advanced screening tests, active measures from the governments, and private associations along with the rising consciousness for the syphilis infections largely contributed to the growth of the market.
Some of the key players that fuel the growth of the syphilis testing market comprise Abbott Diagnostic, Alere, Beckman Coulter, Siemens Healthcare, and Roche Diagnostics, AccuBioTech, Becton Dickinson and Company, Bio-Rad Laboratories, bioLytical Laboratories, Chembion Diagnostic Systems, Diasorin, DRG International, Grifols, IBL International, MEd Mira, Omega Diagnostics, Trinity Biotech, Ulti med Products, and ZEUS Scientific. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.
Browse Related Category Market Reports @
Comentarios